We are live on ! Find out more
PHIO icon

Phio Pharmaceuticals
PHIO

2 hedge funds and large institutions have $6.95M invested in Phio Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

12.17% more ownership

Funds ownership: 0% → 12.17% (+12%)

Holders
2
Holders Change
+2
Holders Change %
–
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Broadfin Capital
Broadfin Capital
New York
+$6.35M
2
Numeric Investors
Numeric Investors
Massachusetts
+$3.18M

Top Sellers

No sellers this quarter

PHIO Hedge Fund Activity: Q1 2014 in Review

2 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q1 2014, worth a combined $6.95M.

Buyers outnumbered sellers: 2 funds opened new PHIO positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Broadfin Capital, opening a new position worth an estimated $6.35M.

  • 2 institutional investors held Phio Pharmaceuticals (PHIO) as of Q1 2014, up from 0 in Q4 2013.
  • Funds reported $6.95M of Phio Pharmaceuticals stock for Q1 2014.
  • 2 funds opened new Phio Pharmaceuticals positions in Q1 2014 and 0 closed out, a net change of +2 holders.
  • The largest Phio Pharmaceuticals buyer in Q1 2014 was Broadfin Capital, an estimated $6.35M added.

Based on aggregated 13F filings for Q1 2014.